Literature DB >> 22460050

Chronic inflammation, albuminuria, and functional disability in older adults with cardiovascular disease: the National Health and Nutrition Examination Survey, 1999-2008.

Hsu-Ko Kuo1, Soham Al Snih, Yong-Fang Kuo, Mukaila A Raji.   

Abstract

OBJECTIVE: Although C-reactive protein (CRP) and albuminuria are well-documented cardiovascular risk markers, the functional implications of these biomarkers and their combination on functional disability and metabolic risks in patients with cardiovascular disease (CVD) are unknown.
METHODS: Data were from 1403 adults (≥60 years, mean 73.2 years) with CVD, ascertained by self-reported diagnosis of angina, coronary heart disease, congestive heart failure, myocardial infarction or stroke, in the National Health and Nutrition Examination Survey 1999-2008. Disability in activities of daily living (ADL), instrumental activities of daily living (IADL), leisure and social activities (LSA), general physical activities (GPA), and lower-extremity mobility (LEM) were obtained from self-reports. The urinary albumin-to-creatinine ratio (UACR) was calculated by dividing the urinary albumin value by the urinary creatinine concentration. CRP levels were quantified by latex-enhanced nephelometry.
RESULTS: Inflammation and albuminuria were associated with disability. In the full-adjusted models, odds ratios (ORs) (95% confidence intervals [CIs]) of disability in ADL, LSA, and LEM were 1.60 (1.13-2.28), 1.76 (1.22-2.55) and 2.31 (1.62-3.31), respectively, comparing participants in the highest CRP quartile to the lowest (p values for trend across CRP quartiles<0.01). The corresponding ORs (95% CI) for disability in ADL, IADL, LSA, and LEM were 1.71 (1.20-2.45), 1.72 (1.21-2.45), 1.46 (1.01-2.12) and 2.50 (1.73-3.62), respectively, comparing participants in the highest UACR quartile to the lowest. We found combined association of inflammation and albuminuria with disability and with metabolic risks. Based on medians of both UACR and CRP, subjects with both higher levels of both markers had higher odds of disability and a more unfavorable metabolic profile than those with lower levels.
CONCLUSIONS: Elevated levels of CRP and UACR independently correlate with disability among older adults with CVD. There is a combined association of inflammation and albuminuria on multiple domains of disability and metabolic risks, suggesting the presence of elevated UACR may amplify the association of inflammation with disability and with metabolic risk in older adults living with CVD.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22460050     DOI: 10.1016/j.atherosclerosis.2012.03.004

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  15 in total

1.  Relationship of Physician Counseling to Weight Loss Among Patients With Nonalcoholic Fatty Liver Disease: An Observational Cohort Study Using National Health and Education Survey Data.

Authors:  Jessica P E Davis; Zachary H Henry; Curtis K Argo; Patrick G Northup
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-11-06

2.  Associations of the antioxidant capacity and hemoglobin levels with functional physical performance of the upper and lower body limbs.

Authors:  Beatriz Caballero; Adrián Rubio-González; Yaiza Potes; Marta Martínez-Reig; Pedro Manuel Sánchez-Jurado; Luis Romero; Juan José Solano; Pedro Abizanda; Ana Coto-Montes
Journal:  Age (Dordr)       Date:  2014-01-03

3.  Urinary albumin, protein excretion and circadian blood pressure in patients with fibromyalgia.

Authors:  Baris Afsar; Rukuye Burucu
Journal:  Rheumatol Int       Date:  2013-04-16       Impact factor: 2.631

4.  Functional Dependence and Mortality in the International Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  S Vanita Jassal; Angelo Karaboyas; Leah A Comment; Brian A Bieber; Hal Morgenstern; Ananda Sen; Brenda W Gillespie; Patricia De Sequera; Mark R Marshall; Shunichi Fukuhara; Bruce M Robinson; Ronald L Pisoni; Francesca Tentori
Journal:  Am J Kidney Dis       Date:  2015-11-21       Impact factor: 8.860

5.  Change in health-related quality of life and social cognitive outcomes in obese, older adults in a randomized controlled weight loss trial: Does physical activity behavior matter?

Authors:  Jason Fanning; Michael P Walkup; Walter T Ambrosius; Lawrence R Brawley; Edward H Ip; Anthony P Marsh; W Jack Rejeski
Journal:  J Behav Med       Date:  2017-11-22

6.  Association of Reduced eGFR and Albuminuria with Serious Fall Injuries among Older Adults.

Authors:  C Barrett Bowling; Samantha G Bromfield; Lisandro D Colantonio; Orlando M Gutiérrez; Daichi Shimbo; Kristi Reynolds; Nicole C Wright; Jeffrey R Curtis; Suzanne E Judd; Harold Franch; David G Warnock; William McClellan; Paul Muntner
Journal:  Clin J Am Soc Nephrol       Date:  2016-04-18       Impact factor: 8.237

7.  An Examination of Lower Extremity Function and its Correlates in Older African American and White Men.

Authors:  Olivio J Clay; Roland J Thorpe; Larrell L Wilkinson; Eric P Plaisance; Michael Crowe; Patricia Sawyer; Cynthia J Brown
Journal:  Ethn Dis       Date:  2015-08-07       Impact factor: 1.847

8.  Peripheral Inflammation and Functional Decline in the National Health and Nutrition Examination Survey Elderly Population.

Authors:  Aaron F Pannone; Xin-Qun Wang; Laurie R Archbald-Pannone
Journal:  J Am Geriatr Soc       Date:  2016-03       Impact factor: 5.562

9.  Community Weight Loss to Combat Obesity and Disability in At-Risk Older Adults.

Authors:  W Jack Rejeski; Walter T Ambrosius; Jonathan H Burdette; Michael P Walkup; Anthony P Marsh
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2017-10-12       Impact factor: 6.053

10.  Examination of the Allostatic Load Construct and Its Longitudinal Association With Health Outcomes in the Boston Puerto Rican Health Study.

Authors:  Andrea López-Cepero; Amanda C McClain; Milagros C Rosal; Katherine L Tucker; Josiemer Mattei
Journal:  Psychosom Med       Date:  2022-01-01       Impact factor: 4.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.